Fetal cardiac arrhythmias: transplacental treatment options

Fetal cardiac rhythm disorders can change rapidly, yet many are detectable before birth and treatable through medication given to the pregnant patient. The clinical goal is not simply to normalize a number on a monitor. It is to preserve cardiac output, prevent hydrops fetalis, support placental and fetal circulation, and choose the safest timing and location for delivery.

The subject belongs to the wider field of perinatal and neonatal medicine highlighted by the FAOPS 2020 congress site, which brought together research and clinical perspectives from Asian and Oceania perinatal societies. Fetal cardiology sits at the intersection of maternal pharmacology, fetal echocardiography, obstetrics, neonatology, and pediatric electrophysiology.

Treatment decisions require individualized assessment. Gestational age, the rhythm mechanism, ventricular function, hydrops, placental transfer, maternal health, and local expertise all influence the plan. A medication that is useful for one fetal tachycardia may be ineffective or unsafe for another rhythm disturbance.

What makes fetal rhythm disorders urgent

Fetal arrhythmias are commonly divided into tachyarrhythmias, bradyarrhythmias, and irregular rhythms. Premature atrial contractions are often benign and may resolve without intervention, although blocked atrial bigeminy or progression to sustained tachycardia requires surveillance. Sustained supraventricular tachycardia, atrial flutter, and less common ventricular tachycardia can reduce ventricular filling and cardiac output.

The danger increases when a rapid rhythm persists or when the fetal heart cannot compensate. Ultrasound may show ventricular dysfunction, tricuspid regurgitation, cardiomegaly, ascites, pleural or pericardial effusion, skin edema, or placental thickening. These findings indicate hydrops fetalis or impending heart failure and make prompt specialist treatment more important.

Bradycardia has a different set of causes. Sinus bradycardia can reflect fetal distress, medication exposure, or structural disease, while congenital complete atrioventricular block is often associated with maternal anti-Ro/SSA or anti-La/SSB antibodies. A low ventricular rate, poor cardiac output, and hydrops are especially concerning, but stable immune-mediated heart block may follow a different management pathway from acute fetal compromise.

Diagnosis before selecting a drug

A fetal echocardiogram should establish the atrial and ventricular rates, the relationship between atrial and ventricular activity, and the mechanism of the rhythm. M-mode imaging and pulsed-wave Doppler can show whether atrial contractions are conducted, blocked, or dissociated from ventricular contractions. This distinction separates re-entrant supraventricular tachycardia from atrial flutter, for example.

The examination should also assess anatomy, ventricular performance, valve regurgitation, umbilical and venous Doppler findings, and evidence of hydrops. A rhythm diagnosis based only on a rapid or slow heart rate is insufficient. The same ventricular rate can arise from different mechanisms that respond differently to antiarrhythmic therapy.

Maternal evaluation is equally important before transplacental treatment begins. Baseline electrocardiography, blood pressure, electrolyte testing, renal and hepatic assessment, medication review, and a history of cardiac disease help identify avoidable risk. Fetal treatment exposes the mother to therapeutic drug concentrations, so maternal safety is part of the fetal treatment plan rather than a separate concern.

How transplacental therapy works

Transplacental treatment uses maternal medication to reach the fetus through the placenta. The amount transferred depends on protein binding, lipid solubility, molecular size, placental metabolism, gestational age, maternal blood concentration, and fetal condition. Hydrops can reduce effective delivery to the fetal myocardium because edema and poor circulation alter distribution.

Digoxin has traditionally been used for fetal supraventricular tachycardia, especially when hydrops is absent or limited. It may slow atrioventricular nodal conduction and improve rate control. Its placental transfer can be less reliable in severe hydrops, and the therapeutic window is narrow. Maternal nausea, visual symptoms, rhythm changes, and drug interactions require attention, with serum levels interpreted alongside clinical findings rather than used in isolation.

Flecainide is effective for many cases of fetal supraventricular tachycardia and may be particularly useful when rapid conversion is needed or hydrops reduces digoxin transfer. It can widen the maternal QRS complex and provoke proarrhythmic effects, so electrocardiographic surveillance and specialist dosing are essential. Sotalol, which combines beta-blocking and antiarrhythmic activity, is commonly considered for atrial flutter and selected tachyarrhythmias, but maternal bradycardia, hypotension, and QT prolongation must be monitored.

Amiodarone is generally reserved for difficult or refractory cases because maternal and fetal adverse effects can be significant. It has a long half-life and may affect thyroid function. In some treatment protocols, combinations such as digoxin with flecainide or sotalol are used, but combination therapy should be directed by a fetal cardiology and maternal-fetal medicine team with experience in antiarrhythmic pharmacology.

Treating bradycardia and immune-mediated block

Transplacental treatment is less predictable for established complete heart block than for fetal tachycardia. Maternal corticosteroids may be considered when active myocardial inflammation or evolving conduction disease is suspected, although they do not reliably restore conduction once complete block is established. Intravenous immunoglobulin and other immune-modulating strategies have been studied in selected settings, but evidence varies and treatment should be individualized.

Hydroxychloroquine may reduce the risk of recurrent anti-Ro/SSA or anti-La/SSB-associated congenital heart block in future pregnancies when started under specialist guidance. It is not a simple rescue treatment for every fetus with established block. Maternal autoimmune history, antibody status, serial fetal rhythm assessment, and signs of myocarditis or cardiomyopathy all inform the decision.

Serial surveillance is particularly important between approximately 16 and 26 weeks, when immune-mediated conduction disease may develop. Home heart-rate monitoring cannot replace formal fetal echocardiography. If the ventricular rate remains stable and cardiac function is preserved, expectant management may be safer than exposing the mother and fetus to medications with uncertain benefit.

Balancing medication, delivery, and neonatal care

The response to therapy is judged by more than rhythm conversion. Clinicians look for improved ventricular function, reduction of valve regurgitation, resolution of venous Doppler abnormalities, and recovery from hydrops. Fetal heart rate tracings alone may be misleading because the fetus can maintain an apparently acceptable rate while cardiac output deteriorates.

If medication fails, gestation is advanced, or fetal status worsens, delivery may become the safest intervention. The decision depends on fetal lung maturity, the severity of hydrops, the likelihood of treatment response, and whether neonatal cardiology, intensive care, respiratory support, and pacing are available immediately. A planned birth at a tertiary center is often preferable to an emergency transfer after sudden decompensation.

The care plan should anticipate the transition from fetal to neonatal circulation. Some antiarrhythmic drugs remain active after birth, and neonatal ECG monitoring may be needed to detect bradycardia, conduction delay, QT changes, or recurrent tachycardia. Neonatal echocardiography and laboratory testing help determine whether the original rhythm problem has resolved or reflects underlying structural or myocardial disease.

Safety, differential diagnosis, and coordinated care

Maternal adverse effects can limit fetal treatment before the fetus shows improvement. Palpitations, syncope, chest discomfort, marked fatigue, hypotension, and breathing difficulty require urgent assessment. The risk of QT prolongation rises with electrolyte abnormalities and interacting drugs, including some antibiotics, antiemetics, and psychiatric medications. Clear instructions about symptoms and follow-up reduce avoidable delays.

Not every fetus with a fast rate has a primary electrical disorder. Myocarditis, cardiomyopathy, structural heart disease, anemia, infection, placental dysfunction, and maternal medication exposure can alter fetal cardiac performance. Maternal cardiac disease also deserves attention; resources discussing peripartum cardiomyopathy care illustrate why maternal ventricular function must be assessed when symptoms or risk factors suggest heart disease.

Care is strongest when fetal cardiology, maternal-fetal medicine, obstetrics, pharmacy, neonatology, and pediatric electrophysiology communicate through a shared plan. Documentation should include the suspected rhythm, treatment target, maternal monitoring schedule, fetal assessment interval, criteria for escalation, and delivery arrangements. Cross-border and emergency planning also matter, particularly when specialized fetal therapy is unavailable locally. Broader lessons about resilient perinatal systems apply directly to maintaining referral pathways and neonatal capacity.

Practical priorities for clinical planning

• Confirm the rhythm mechanism with fetal echocardiography before choosing an antiarrhythmic drug.
• Assess hydrops, ventricular function, structural anatomy, maternal ECG, electrolytes, and medication interactions at baseline.
• Use a fetal cardiology and maternal-fetal medicine protocol for dose selection, escalation, and response assessment.
• Monitor maternal toxicity and fetal hemodynamics together rather than treating the fetal heart rate as the only endpoint.
• Arrange delivery where neonatal intensive care, pediatric cardiology, and pacing or advanced rhythm management are immediately available.

Early referral can preserve more options, especially when sustained tachycardia appears before hydrops develops. Families should receive a clear explanation of the suspected rhythm, the purpose and limitations of transplacental medication, possible maternal side effects, expected monitoring, and circumstances that would prompt delivery.

A careful, mechanism-based plan gives clinicians the best chance of protecting both patients. Use established local protocols, involve the appropriate specialists early, and ensure that every pregnancy with a significant fetal arrhythmia has a documented pathway from diagnosis through maternal treatment, delivery, and neonatal follow-up.